Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 11/20 | 0.45 |
| ▸ | CTSK | P43235 | 10/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13649290 | 0.90 | CTSS (0.47) | AKT1CTSSCTSKCTSBCTSL | |
| SCHEMBL4122244 | 0.85 | MALT1 (0.45) | AKT1CTSSCTSKCA2MALT1 | |
| SCHEMBL13649295 | 0.85 | MALT1 (0.45) | AKT1CTSSCTSKCA2MALT1 | |
| SCHEMBL4122496 | 0.83 | MALT1 (0.57) | AKT1CA2MALT1 | |
| SCHEMBL13649297 | 0.83 | CA2 (0.58) | CTSSCTSKCA2MALT1 | |
| SCHEMBL4110696 | 0.83 | CA2 (0.58) | CTSSCTSKCA2MALT1 | |
| SCHEMBL13649299 | 0.81 | CA2 (0.48) | AKT1CTSSCTSKCA2MALT1 | |
| SCHEMBL4121126 | 0.80 | CTSL (0.65) | CTSSCTSKCTSL | |
| SCHEMBL14386438 | 0.80 | CTSS (0.45) | AKT1CTSSCTSKCTSBCTSL | |
| SCHEMBL4116583 | 0.78 | MALT1 (0.49) | AKT1CA2MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | FLUOFARMA (FR) | 2009-10-01 | — | — | US | disclosed |
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | FLUOFARMA (FR) | 2009-10-01 | — | — | US | disclosed |
| WO-2007125196-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | FLUOFARMA (FR) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | CCNA1, MKI67, CCNT1 | AKT1 1691/4885CTSS 2707/4885CTSK 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.